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Short review Towards an anti-fibrotic therapy for scleroderma: 




Background: In response to normal tissue injury, fibroblasts migrate into the wound where they synthesize and 
remodel new extracellular matrix. The fibroblast responsible for this process is called the myofibroblast, which 
expresses the highly contractile protein α-smooth muscle actin (α-SMA). In normal tissue repair, the myofibroblast 
disappears. Conversely, abnormal myofibroblast persistence is a key feature of fibrotic dieases, including scleroderma 
(systemic sclerosis, SSc). Myofibroblasts can be derived from differentiation of local resident fibroblasts or by 
recruitment of microvascular pericytes.
Clinical problem addressed: Controlling myofibroblast differentiation and persistence is crucial for developing anti-
fibrotic therapies targeting SSc.
Basic science advances: Insights have been recently generated into how the proteins transforming growth factor β 
(TGFβ), endothelin-1 (ET-1), connective tissue growth factor (CCN2/CTGF) and platelet derived growth factor (PDGF) 
contribute to myofibroblast differentiation and pericyte recruitment in general and to the persistent myofibroblast 
phenotype of lesional SSc fibroblast, specifically.
Relevance to clinical care: This minireview summarizes recent findings pertinent to the origin of myofibroblasts in 
SSc and how this knowledge might be used to control the fibrosis in this disease.
Conclusions: TGFβ, ET-1, CCN2 and PDGF are likely to cooperate in driving tissue repair and fibrogenic responses in 
fibroblasts. TGFβ, ET-1 and CCN2 appear to contribute to myofibroblast differentiation; PDGF appears to be involved 
with pericyte recruitment. Thus, different therapeutic strategies may exist for targeting the multisystem fibrotic 
disorder SSc.
Introduction
When connective tissue is damaged, fibroblasts migrate
into the wound and begin to produce and remodel extra-
cellular matrix (ECM) [1]. These events involve a specific
sort of fibroblast termed the myofibroblast, a cell type
which expresses the highly contractile protein α-smooth
muscle actin (α-SMA) [1]. The α-SMA protein is orga-
nized into stress fibres which are connected to the ECM
through specialized so-called 'supermature' FAs. As a
result, these α-SMA stress fibers can contract and exert
mechanical tension on the ECM causing it to be reorga-
nized into functional connective tissue. Myofibroblast
persistence is believed to be responsible for fibrotic dis-
eases including scleroderma (SSc; Figure 1) [1,2].
Myofibroblasts have multiple origins, possibly appear-
ing, for example, by differentiation of local, resident
fibroblasts in response to proteins or by the migration of
microvascular pericytes into the lesional area [1] (Figure
1). Understanding how myofibroblasts may originate may
be useful in understanding how to combat the fibrosis
observed in SSc, and this is the subject of this minireview.
Transforming growth factor-β (TGF-β)
Extensive reviews on TGFβ signalling and the contribu-
tion of this pathway to experimentally-induced fibrosis
have been published elsewhere (for example, see [3]).
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Briefly, there are three TGFβ isoforms, TGFβ1, TGFβ2
and TGFβ3. These are initially generated as latent precur-
sors from which active TGFβ is liberated by proteolysis,
enabling it to bind to a heteromeric receptor complex
consisting of one TGFβ type I [termed activin linked
kinase 5 (ALK5) in the case of fibroblasts] and one TGFβ
type II receptor. ALK5 phosphorylates Smad2 and 3,
which can then bind Smad4, translocates into the nucleus
and activate transcription. The ALK5/Smad pathway is
generally responsible for TGFβ signalling in fibroblasts.
In normal fibroblasts, ALK5 appears to mediate the fibro-
genic activity of TGFβ [4]. Recombinant TGFβ is fibro-
genic in both in vitro and in vivo models of fibrogenesis,
acting through ALK5/Smad3 [3]. The contribution of this
canonical TGFβ pathway on the persistent fibrotic phe-
notype of lesional SSc fibroblasts has been evaluated.
Targeting ALK5, using small molecule inhibitors,
r e v e r s e s  s o m e  a s p e c t s  o f  l e s i o n a l  d e r m a l  s c l e r o d e r m a
fibroblasts but, critically, does not reduce α-SMA or
CCN2 protein expression or α-SMA stress fibre forma-
tion in this cell type [2,5,6]. These results are consistent
with data showing that Smad3 is not involved with CCN2
overexpression in SSc fibroblasts [7]. These observations
exist in spite of the fact that there is a trend towards
heightened Smad3 phosphorylation and nuclear localiza-
tion in SSc fibroblasts compared to their healthy counter-
parts [8].
An interesting series of recent experiments have sug-
gested the possibility that heightened activity of Smad1
may contribute to the pathogenesis of SSc [9]. This phe-
nomenon appears to arise due to an alteration in the ratio
of the levels of the TGFβ type I receptor to the TGFβ type
II receptor. In SSc fibroblasts, there is an elevation in the
amount of the TGFβ type I receptor which may contrib-
ute to the overexpression of type I collagen in these cells
[10]. Overexpression of ALK5 caused an increase in colla-
gen production by fibroblasts [10,11]. This up-regulation
of collagen does not appear to involve the kinase activity
of ALK5 or Smad2/3 activation but experiments using
mutant TGFβ receptors and siRNAs show that this phe-
nonomenon appears to be mediated by ALK1/Smad1 and
ERK1/2 pathways [9]. Overall, these data suggest that
canonical ALK5/Smad signalling is likely to contribute to
but not be the fundamental basis of the persistent fibrotic
phenotype of lesional SSc fibroblasts and suggest that
blocking non-canonical TGFβ pathways may be a better
alternative in combating the persistent fibrotic phenotype
in SSc [12,13].
In addition to the ALK5/Smad pathway, TGFβ activates
additional signalling pathways including: ras/MEK/ERK,
which requires the heparan sulphate-containing proteo-
glycan (HSPG) syndecan 4; p38, which requires the
HSPG betaglycan and JNK which requires focal adhesion
kinase (FAK) and TGFβ activated kinase 1 (TAK1)
[2,14,15]. These pathways appear to modify gene expres-
sion in a promoter-selective fashion. For example, FAK,
JNK and TAK1 are required for myofibroblast differentia-
tion and α-SMA expression [14,15]. Whereas extra cellu-
lar signal-regulated kinase (ERK) is required for CCN2
and collagen type I expression [16,17], p38 appears to be
not involved with the fibrogenic activity of TGFβ [4].
Constitutive TAK1 and JNK activation independent of
ALK5 is seen in SSc fibroblasts [14,18]; thus, it is likely
that signalling pathways are abnormally activated in SSc
fibroblasts in a fashion independent of the canonical
T G F β  p a t h w a y .  I t  i s  l i k e l y  t h a t  t a r g e t i n g  F A K,  J N K  o r
TAK1 may be beneficial in alleviating the persistent SSc
phenotype of dermal fibroblasts.
Endothelin-1 (ET-1)
There are 3 isoforms of endothelin, namely ET-1, ET-2,
and ET-3 [12]. ET-1, the significant isoform in humans, is
normally produced by a variety of cell types including
endothelial cells, epithelial cells, bone marrow mast cells,
macrophages, polymorphonuclear leukocytes, cardio-
myocytes, and fibroblasts [12]. Initially, ET-1 is produced
in the form of a 212-amino acid precursor (prepro-ET-1)
which is enzymatically cleaved to form a biologically
active 21-amino acid peptide [12]. ET-1 can then bind its
two receptors (ETA and ETB) [12].
ET-1 induces ECM production in fibroblasts through
the ETA and ETB receptors and MEK/ERK, whereas ET-1
induces myofibroblast formation, migration and ECM
contraction through ETA and Akt/rac [19,20] (Figure 1).
TGFβ induces ET-1 through JNK, and ET-1 is a down-
stream mediator of at least some of fibrotic responses of
fibroblasts to TGFβ [18,21]. Constitutive ET signalling,
operating through TAK1/JNK-dependent and ALK5-
independent mechanisms, is responsible for the persis-
tent myofibroblast phenotype of SSc lung fibroblasts [18].
Consistent with the notion that ET-1 contributes to fibro-
sis in the lung, ET receptor antagonism alleviates bleomy-
cin-induced lung fibrosis and TGFβ-induced skin
fibrogenesis  in vivo [22,23]. However, the effect of ET
Figure 1 Model of myofibroblast origin in skin lesions of sclero-
derma patients. Transforming growth factor β, endothelin-1 and 
CCN2 can enhance differentiation of resident fibroblasts to myofibro-
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inhibition on SSc dermal fibroblasts has not yet been
tested. TGFβ appears to also cooperate with ET-1 to pro-
mote myofibroblast differentiation [24]. The ET receptor
antagonist bosentan may also be effective at reducing
skin fibrosis in patients with SSc [25]. These results sug-
gest that endothelin receptor antagonism might be con-
sidered as an appropriate therapy for the fibrosis in SSc,
possibly in combination with anti-TGFβ regimens.
CCN2
CCN2, a member of the CCN family of matricellular pro-
teins, is an excellent surrogate marker for the severity of
fibrosis in SSc [26]. CCN2 signals through a variety of
integrins and HSPGs or trkA and promotes cell adhesion
and enhances adhesive signaling in response to extracel-
lular ligands [27]. CCN2 is induced by both TGFβ and
ET-1 and is considered to be a downstream mediator of
these proteins [12]. The CCN2 promoter appears to pos-
sess independent TGFβ and ET-1 response elements
[16,20] and thus may be a common downstream mediator
of the fibrotic effects of these proteins, and thus may rep-
resent a more attractive target than either protein alone.
CCN2 acts as a cofactor with TGFβ to induce fibrogen-
esis but is not considered to be a potent fibrogenic agent
on its own [28,29] (Figure 1). However, a recent study
revealed chronic overexpression of CCN2 can lead to a
fibrotic phenotype [30]. CCN2 is not required for all of
the activities of TGFβ actions but appears to be required
for TGFβ to maximally induce certain mRNAs including
type I collagen and α-SMA and for TGFβ to promote cell
adhesion to ECM [31] (Figure 1). CCN2 also can activate
ERK by a syndecan 4-dependent mechanism [32]. A
CCN2 response element exists in the COL1A2 promoter;
blocking CCN2 action using an anti-CCN2 antibody or
siRNA reduces some effects of bleomycin-induced lung
fibrosis [33]. Overall, the available data suggest that tar-
geting CCN2 may be useful in combating fibrosis in SSc.
Platelet derived growth factor (PDGF)
The PDGF family includes PDGF-AA, PDGF-AB, PDGF-
BB, PDGF-CC and PDGF-DD. These bind two different
PDGF receptors, α and β [34]. PDGF causes neutrophils,
macrophages, fibroblasts and smooth muscle cells to pro-
liferate and migrate into the wound site [34]. In vitro,
PGDF stimulates fibroblasts to contract collagen matrices
and differentiate into myofibroblasts [35].
Studies have revealed that PDGF levels are elevated in
the bronchial lavage fluid of SSc patients, as well as ele-
vated levels of the PDGFβ receptors on SSc fibroblasts
[36-38]. Moreover, one study has been reported showing
that autoantibodies stimulating the PDGF receptor may
be a hallmark of SSc [39].
Mice treated with PDGFβ receptor- inhibitor imatinib
mesylate, a tyrosine kinase inhibitor exhibit delayed cuta-
neous wound closure, diminished numbers of myofibro-
blast numbers and reduced collagen type I expression
[40]. Imatinib mesylate did not prevent the myofibroblast
differentiation in vitro but inhibited fibroblast prolifera-
tion and migration and appeared to principally act by
blocking pericyte recruitment [40] (Figure 1). As a subset
(~30%) of myofibroblasts in cutaneous mouse wounds
are NG2-positive pericytes, this phenomenon is likely to
lead to the reduction myofibroblasts in the wound [41].
Intriguingly, however, the majority (~70%) of myofibro-
blasts in bleomycin-induced skin fibrosis are derived
from pericytes [42]. Tyrosine kinase inhibitors analogous
to imatinib mesylate blocked bleomycin-induced dermal
fibrosis in mice [43]. It is also interesting to note that ima-
tinib mesylate also blocks the ability of TGFβ to activate
Smad 1 and the transcription factor egr-1 via c-abl,
emphasizing the potential of signalling crosstalk between
PDGF and non-canonical TGFβ signalling and further
suggesting that this inhibitor may also work by blocking
non-canonical TGFβ signalling [44,45]. Given that peri-
cytes contribute to myofibroblast activation in SSc [46],
these results collectively suggest that perhaps targeting
PDGF/c-abl might be of benefit in SSc through its ability
to block pericyte recruitment. As such, anti-PDGF drugs
may represent a different sort of approach to alleviating
SSc than blocking growth factor differentiation of resi-
dent fibroblasts, which may be of lesser importance than
pericyte recruitment in generating a source of myofibro-
blasts in fibrosis.
Future Prospects and Conclusions
TGFβ, ET-1, CCN2 and PDGF are likely to cooperate in
driving tissue repair and fibrogenic responses in lesional
SSc fibroblasts. However, these proteins seem to be
responsible, for somewhat differing activities suggesting
that combination therapies may be appropriate for SSc.
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